About Event
What you missed in 2023:
CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders, through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition.
Returning to Boston, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit was the only industry-specific meeting dedicated to developing translatable, scalable, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials.
This was your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development.
Join Pioneering Digital Health Leaders to Hear From:
On showcasing takeaways from utilizing wearable sensors in decentralized clinical trialsto sensitively measure gait and cognitive disease metrics
To breakdown the journey to regulatory approval of novel digital measures and methods to best instill confidence in regulatory bodies
To explore the best practices to select and validate disease-specific digital measures in neurological indications with poor anchors
On outlining key design considerations in usability of wearable and non-wearable technologies to maximize patient engagement through clinical data collection
To understand methods in digital measure rationale and design to optimize incorporation of novel measures into existing clinical trial frameworks
On adapting a patient co-centric approach to create clinically meaningful digital measures of movement and gait
Who Will You Meet in 2023?
The 2nd Digital Biomarkers & Clinical Measures in Neurology Summit will bridge the gap between data scientists and biostatisticians optimizing the development and validation of digital measurements, and clinical scientists and digital health leaders tackling industry’s transition to integrate clinically meaningful digital tools into their CNS pipelines.
Don’t miss your chance to meet and network with 80+ digital biomarkers KOLs, data scientists and biostatisticians, digital health pioneers, wearable technology specialists, digital therapeutic developers, patient innovation leaders, and digital regulatory experts.
With AbbVie, Biogen Digital Health, Regeneron, Cognito Therapeutics, and more set to deliver case study presentations, this is your must-attend meeting to hear from leading experts driving the digital revolution of biomarkers and endpoints in CNS clinical trials.